ITPK6 Antibody

What is ITPK1 and what role does it play in cellular functions?

ITPK1 (Inositol-tetrakisphosphate 1-kinase) is a key enzyme involved in inositol phosphate metabolism that catalyzes the phosphorylation of various inositol phosphate substrates. The protein plays crucial roles in signal transduction pathways and has been implicated in several developmental processes. The ITPK1 gene has been particularly associated with neural tube defects resulting in spina bifida . The protein has a molecular weight of approximately 46 kDa and is expressed in multiple tissue types. In cellular signaling pathways, ITPK1 functions alongside other kinases to regulate calcium mobilization and cellular responses to external stimuli.

What species reactivity does the ITPK1 antibody demonstrate?

The commercially available ITPK1 antibodies demonstrate reactivity against human, mouse, and rat species (H, M, R) . This cross-species reactivity makes the antibody particularly valuable for comparative studies across different model organisms. When planning experiments involving other species, researchers should perform preliminary validation studies to confirm cross-reactivity or consult with manufacturers regarding species-specific variants of the antibody.

What are the standard applications for ITPK1 antibody?

ITPK1 antibody has been validated for several standard laboratory applications, with primary uses in:

The antibody shows endogenous sensitivity, making it suitable for detecting native expression levels without overexpression systems .

What are the optimal experimental conditions for Western blotting with ITPK1 antibody?

When performing Western blotting with ITPK1 antibody, researchers should consider the following protocol optimizations:

• Sample preparation: Total cell lysates or tissue homogenates should be prepared using RIPA or similar lysis buffers containing protease inhibitors.

• Protein loading: 20-40 μg of total protein per lane is generally sufficient for detection of endogenous ITPK1.

• Blocking conditions: 5% non-fat dry milk or 5% BSA in TBST (Tris-buffered saline with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody incubation: Dilute ITPK1 antibody 1:1000 in blocking buffer and incubate overnight at 4°C .

• Secondary antibody: Anti-rabbit HRP-conjugated secondary antibody at 1:2000-1:5000 dilution for 1 hour at room temperature.

For optimal band resolution and reproducibility, researchers should run protein samples alongside molecular weight markers and positive control samples to confirm detection specificity.

How can researchers validate the specificity of ITPK1 antibody?

Antibody specificity validation is critical for ensuring reliable experimental results. Multiple approaches should be employed:

• Knockout/knockdown controls: Compare detection in wild-type samples versus ITPK1 knockout or knockdown samples, which should show reduced or absent signal.

• Blocking peptide experiments: Pre-incubate the antibody with purified ITPK1 protein or immunizing peptide before application to samples, which should eliminate specific binding.

• Multiple antibody approach: Use alternative antibodies targeting different epitopes of ITPK1 and confirm consistent detection patterns.

• Mass spectrometry validation: Following immunoprecipitation, analyze pulled-down proteins by mass spectrometry to confirm ITPK1 presence .

These validation steps are particularly important when examining tissues or cell types where ITPK1 expression has not been previously characterized.

What challenges might arise when using ITPK1 antibody in immunoprecipitation?

Immunoprecipitation with ITPK1 antibody may present several technical challenges:

• Non-specific binding: ITPK1 may form complexes with other proteins, resulting in co-precipitation of interaction partners that could be interpreted as non-specific binding.

• Low abundance: In certain cell types or conditions, ITPK1 expression might be limited, requiring optimization of starting material amounts.

• Antibody cross-reactivity: At the recommended 1:50 dilution for IP applications , researchers should be vigilant for potential cross-reactivity with structurally similar proteins.

• Buffer compatibility: Certain buffer components may interfere with antibody-epitope interactions; testing multiple lysis buffer formulations may be necessary.

To address these challenges, researchers should include appropriate negative controls (such as IgG-only precipitations) and may need to optimize detergent concentrations in lysis buffers to maintain protein-protein interactions while facilitating effective antibody binding.

How does ITPK1 relate to neural tube defects and what research models are available?

Mutations in the ITPK1 gene have been identified as risk factors for neural tube defects (NTDs) resulting in spina bifida . The connection between ITPK1 and NTDs has been explored in several research models:

• Mouse models: ITPK1 knockout mice exhibit phenotypes similar to human neural tube defects, providing in vivo systems for studying the protein's developmental roles.

• Cell culture models: Neural progenitor cells with manipulated ITPK1 expression have been used to study mechanisms underlying neural tube formation.

• Human genetic studies: Genome-wide association studies have identified ITPK1 variants associated with increased NTD risk.

When investigating ITPK1 in the context of neural development, researchers should consider experimental timing that corresponds to critical developmental windows and should combine antibody-based detection with functional assays to assess enzymatic activity changes associated with pathogenic variants.

Can ITPK1 antibody be used in multiplexed detection systems?

ITPK1 antibody can be incorporated into multiplexed detection systems for comprehensive pathway analysis:

• Co-immunofluorescence: ITPK1 antibody raised in rabbit can be combined with antibodies raised in different host species (mouse, goat) targeting other pathway components for simultaneous detection .

• Sequential immunoblotting: Following ITPK1 detection, membranes can be stripped and reprobed for related proteins to examine expression correlations.

• Mass cytometry: For single-cell analysis, metal-conjugated ITPK1 antibodies can be combined with other labeled antibodies for CyTOF applications.

• Proximity ligation assays: ITPK1 antibody can be used to detect protein-protein interactions in situ when combined with antibodies against suspected interaction partners.

When designing multiplexed experiments, researchers should carefully verify antibody compatibility, including host species, isotypes, and optimal working concentrations for each detection system.

What are common sources of background when using ITPK1 antibody in immunodetection?

Several factors can contribute to background signal when using ITPK1 antibody:

• Insufficient blocking: Increase blocking time or concentration (5-10% blocking agent) to reduce non-specific binding.

• Excessive antibody concentration: Titrate the antibody to determine the optimal working dilution; for Western blotting, test a range around the recommended 1:1000 dilution .

• Cross-reactivity: The antibody may recognize structurally similar proteins, particularly in certain tissue types.

• Sample preparation issues: Incomplete cell lysis or protein degradation can lead to unexpected banding patterns.

• Detection system sensitivity: Highly sensitive chemiluminescent substrates may amplify background signals; consider reduced exposure times or alternative detection systems.

To minimize background, researchers should also perform stringent washing steps between antibody incubations, using fresh TBST or PBST buffers with multiple changes.

How should ITPK1 antibody be stored to maintain optimal activity?

To maintain antibody activity and prevent functional degradation:

• Storage temperature: Store undiluted antibody at -20°C for long-term storage or at 4°C for short-term use (less than one week).

• Avoid freeze-thaw cycles: Repeated freezing and thawing can lead to antibody degradation and loss of activity. Aliquot the antibody upon receipt to minimize freeze-thaw cycles.

• Do not aliquot the antibody: Some commercial ITPK1 antibody preparations specifically recommend against aliquoting the antibody , likely due to formulation considerations.

• Working dilutions: Prepare working dilutions fresh on the day of experiment rather than storing diluted antibody.

• Carrier proteins: Addition of carrier proteins (BSA, gelatin) at 1-5 mg/ml to diluted antibody preparations can help stabilize antibody activity if short-term storage of working dilutions is necessary.

For experiments requiring consistent antibody performance over time, researchers should obtain fresh antibody lots for extended studies and validate lot-to-lot consistency.

How can ITPK1 antibody be used in combination with calcium signaling studies?

Research has shown that inhibition of ITPK1 (Itpkb in the referenced study) augments calcium signaling in lymphocytes , suggesting important applications for ITPK1 antibody in calcium pathway research:

• Live cell imaging: ITPK1 antibody (if cell-permeable or conjugated to cell-penetrating peptides) can be used alongside calcium-sensitive fluorescent dyes to correlate ITPK1 localization with calcium flux.

• Pull-down experiments: ITPK1 antibody can help identify calcium-dependent interaction partners through co-immunoprecipitation under varying calcium concentrations.

• Pharmacodynamic biomarkers: In studies testing ITPK1 inhibitors, the antibody can track protein levels while calcium indicators monitor functional outcomes.

• T cell signaling research: Given that ITPK1 inhibition affects T cell activation , the antibody is valuable for investigating mechanistic connections between inositol metabolism and immune signaling.

These applications are particularly relevant as evidence emerges that ITPK1 inhibitors could potentially modulate T cell-dependent antibody responses and may have therapeutic applications in T cell-driven arthritis models .

What emerging techniques for antibody specificity engineering may improve future ITPK1 antibody development?

Recent advances in antibody engineering offer promising directions for next-generation ITPK1 antibodies:

• Computational inference models: Emerging biophysics-informed computational models can predict antibody binding profiles, allowing researchers to design custom antibody sequences with predefined specificity profiles .

• Cross-specificity engineering: Novel techniques can generate antibodies that either interact specifically with a single ligand while excluding others, or cross-react with multiple desired targets .

• Phage display optimization: Advanced phage display experiments with antibody libraries can select for highly specific binding to ITPK1 versus closely related proteins .

• Energy function optimization: Mathematical approaches involving minimizing or maximizing energy functions associated with antibody-ligand interactions can enhance specificity .

These technological advances may soon enable the development of ITPK1 antibodies with dramatically improved specificity, reduced off-target effects, and enhanced suitability for therapeutic applications.